Anthem Biosciences - Public Comps and Valuation Multiples

Anthem Biosciences Overview

About Anthem Biosciences

Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.

Founded

2006

HQ

Employees

2.1K+

Website

anthembio.com

Sectors

Financials

LTM Revenue $232M

LTM EBITDA $83.9M

EV

$4.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Anthem Biosciences Financials

As of September 2025, Anthem Biosciences reported last 12-month revenue of $232M and EBITDA of $83.9M.

In the same period, Anthem Biosciences generated $137M in LTM gross profit and $58.2M in net income.

See Anthem Biosciences valuation multiples based on analyst estimates

Anthem Biosciences P&L

In the most recent fiscal year, Anthem Biosciences reported revenue of $208M and EBITDA of $85.2M.

Anthem Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Anthem Biosciences valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$232M	XXX	$208M	XXX	XXX	XXX
Gross Profit	$137M	XXX	$124M	XXX	XXX	XXX
Gross Margin	59%	XXX	60%	XXX	XXX	XXX
EBITDA	$83.9M	XXX	$85.2M	XXX	XXX	XXX
EBITDA Margin	36%	XXX	41%	XXX	XXX	XXX
EBIT	$72.1M	XXX	$66.7M	XXX	XXX	XXX
EBIT Margin	31%	XXX	32%	XXX	XXX	XXX
Net Profit	$58.2M	XXX	$50.8M	XXX	XXX	XXX
Net Margin	25%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Anthem Biosciences including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $232M. EBITDA for the last twelve months was $83.9M. In the most recent fiscal year, Anthem Biosciences achieved $208M in revenue and $85.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$232M	Analyst estimates available to subscribers	$208M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$137M	Analyst estimates available to subscribers	$124M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	59.0% gross margin	Analyst estimates available to subscribers	59.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$83.9M	Analyst estimates available to subscribers	$85.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	36.2% EBITDA margin	Analyst estimates available to subscribers	41.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$72.1M	Analyst estimates available to subscribers	$66.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	31.1% EBIT margin	Analyst estimates available to subscribers	32.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$58.2M	Analyst estimates available to subscribers	$50.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.1% net profit margin	Analyst estimates available to subscribers	24.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Anthem Biosciences

This financial data table provides comprehensive performance metrics for Anthem Biosciences, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Anthem Biosciences generated $232M in revenue over the last twelve months.
The company achieved $83.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $137M.
Net income over the last twelve months reached $58.2M.

Fiscal Year Performance

In the most recent fiscal year, Anthem Biosciences reported $208M in total revenue.
Fiscal year EBITDA was $85.2M.
The company maintained a gross profit margin of 59.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was 41.0%.
Net profit margin reached 24.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Anthem Biosciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Anthem Biosciences Stock Performance

Anthem Biosciences has current market cap of INR 433B (or $4.9B), and EV of INR 427B (or $4.8B).

Market Cap Evolution

Anthem Biosciences Stock Data

As of October 3, 2025, Anthem Biosciences's stock price is INR 771 (or $9).

See Anthem Biosciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.8B	$4.9B	XXX	XXX	XXX	XXX	$0.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Anthem Biosciences Valuation Multiples

Anthem Biosciences's trades at 24.6x EV/Revenue multiple, and 60.2x EV/EBITDA.

See valuation multiples for Anthem Biosciences and 15K+ public comps

Anthem Biosciences Financial Valuation Multiples

As of October 3, 2025, Anthem Biosciences has market cap of $4.9B and EV of $4.8B.

Equity research analysts estimate Anthem Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Anthem Biosciences has a P/E ratio of 83.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.9B	XXX	$4.9B	XXX	XXX	XXX
EV (current)	$4.8B	XXX	$4.8B	XXX	XXX	XXX
EV/Revenue	20.7x	XXX	24.6x	XXX	XXX	XXX
EV/EBITDA	57.3x	XXX	60.2x	XXX	XXX	XXX
EV/EBIT	66.7x	XXX	77.6x	XXX	XXX	XXX
EV/Gross Profit	35.1x	XXX	n/a	XXX	XXX	XXX
P/E	83.7x	XXX	100.6x	XXX	XXX	XXX
EV/FCF	317.9x	XXX	1108.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Anthem Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Anthem Biosciences Margins & Growth Rates

Anthem Biosciences's last 12 month revenue growth is 24%

Anthem Biosciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $28K for the same period.

Anthem Biosciences's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Anthem Biosciences's rule of X is 95% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Anthem Biosciences and other 15K+ public comps

Anthem Biosciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	24%	XXX	24%	XXX	XXX	XXX
EBITDA Margin	36%	XXX	41%	XXX	XXX	XXX
EBITDA Growth	26%	XXX	18%	XXX	XXX	XXX
Rule of 40	64%	XXX	64%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	95%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$28K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial